Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results from SPRINT

Stephen P. Juraschek, Addison A. Taylor, Jackson T. Wright, Gregory W. Evans, Edgar R. Miller, Timothy B. Plante, William C. Cushman, Tanya R. Gure, William E. Haley, Imran Moinuddin, John Nord, Suzanne Oparil, Carolyn Pedley, Christianne L. Roumie, Jeff Whittle, Alan Wiggers, Ciarán Finucane, Rose Anne Kenny, Lawrence J. Appel, Raymond R. Townsend

Research output: Contribution to journalArticlepeer-review


Orthostatic hypotension (OH) is frequently observed with hypertension treatment, but its contribution to adverse outcomes is unknown. The SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized trial of adults, age ≥50 years at high risk for cardiovascular disease with a seated systolic blood pressure (BP) of 130 to 180 mm Hg and a standing systolic BP ≥110 mm Hg. Participants were randomized to a systolic BP treatment goal of either <120 or <140 mm Hg. OH was defined as a drop in systolic BP ≥20 or diastolic BP ≥10 mm Hg 1 minute after standing from a seated position. We used Cox models to examine the association of OH with cardiovascular disease or adverse study events by randomized BP goal. During the follow-up period (median 3years), there were 1170 (5.7%) instances of OH among those assigned a standard BP goal and 1057 (5.0%) among those assigned the intensive BP goal. OH was not associated with higher risk of cardiovascular disease events (primary outcome: hazard ratio 1.06 [95% CI, 0.78-1.44]). Moreover, OH was not associated with syncope, electrolyte abnormalities, injurious falls, or acute renal failure. OH was associated with hypotension-related hospitalizations or emergency department visits (hazard ratio, 1.77 [95% CI, 1.11-2.82]) and bradycardia (hazard ratio, 1.94 [95% CI, 1.19-3.15]), but these associations did not differ by BP treatment goal. OH was not associated with a higher risk of cardiovascular disease events, and BP treatment goal had no effect on OH's association with hypotension and bradycardia. Symptomless OH during hypertension treatment should not be viewed as a reason to down-titrate therapy even in the setting of a lower BP goal.

Original languageEnglish (US)
Pages (from-to)660-667
Number of pages8
StatePublished - Mar 1 2020


  • blood pressure
  • cardiovascular disease
  • hypertension
  • orthostatic hypotension
  • syncope

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results from SPRINT'. Together they form a unique fingerprint.

Cite this